Tag:
pancreatic cancer
Latest Headlines
Latest Headlines
Radioactive bacteria treatment stops metastasis in mice
A therapy derived from a weakened version of a deadly kind of bacteria reduced metastasis of pancreatic cancer in mice with no obvious ill effects, according to a new study.
Dx approach offers chance to spot pancreatic cancer earlier
With a five-year survival rate of less than 5%, pancreatic cancer is aggressive, deadly and an all-but-certain death sentence, in part because it is usually metastasized before doctors spot it. Japanese scientists have come up with a blood test that would screen for certain metabolites to help detect the disease earlier than current diagnostics allow, and potentially boost those survival odds.
FDA scrutinizing Merck's Januvia, BMS' Byetta
The FDA is taking a closer look at the increased risk of Type 2 diabetics getting pancreatic cancer from the popular drugs like Merck's blockbuster Januvia and Byetta from Bristol-Myers Squibb.
Celgene's Abraxane shows promise in pancreatic cancer
A drug that Celgene ($CELG) acquired in its $2.9 billion acquisition of Abraxis BioScience in 2010 is showing promise against the notoriously hard-to-treat p ancreatic cancer.
Celgene keeps biotech spotlight with sanguine Abraxane data in pancreatic cancer
Celgene CEO Bob Hugin is leading a push to rapidly grow the major drugmaker, keeping the company atop lists of go-to partners among biotechs.
New target could improve treatment of deadly pancreatic cancer
With the 5-year survival rate for pancreatic cancer at just 6%--the lowest among all major killer cancers--finding a treatment for the disease could literally be lifesaving for patients.
Celgene shares jump on Abraxane pancreatic cancer results
The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.Analysts greeted the data with some impressive sales projections.
Celgene's Abraxane boosts survival in pancreatic cancer
They're popping corks at Celgene ($CELG) headquarters. The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.
Kancera credits new drug with slowing pancreatic cancer tumor growth
Swedish drug developer Kancera says it has slowed the growth of pancreatic cancer tumors in preclinical animal trials with its first-generation PFKFB3 inhibitors.
Phase III finding points to masitinib CDx for pancreatic cancer
A Phase III finding of a set of blood biomarkers could lead to a companion diagnostic to be used alongside masitinib, AB Science's investigational drug for pancreatic cancer.
- « first
- ‹ previous
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
